Creative Medical Technology Holdings, Inc.
corporate_fare Company Profile
Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 19 items for CELZ at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-13, rated 8/10. Across its 19 most recent items scored 7 or higher, the top rating is 9/10, with 12 rated 8 or above. Recent SEC coverage for CELZ spans 8-K, 10-Q, S-3, DEF 14A.
Recent high-impact activity:
- CELZ Receives Nasdaq Bid-Price Deficiency Notice, Has Until May 10, 2027 to Recover
- CELZ Q3 Loss Widens to $5.58M as Cash Slips to $6.85M; 8.48M Warrants Overhang 7.60M Shares
- CELZ Moves to 80% Control of BioDefense in Related-Party Transaction
- CELZ Completes Enrollment and Treatment Across Entire ADAPT Trial, Advancing Olastrocel Toward RMAT and Phase 3
- CELZ Q2 2026: Cash at $8.7M After $4.5M Warrant Exercise, Loss Widens Slightly
Financial Snapshot
Short Interest & Short Volume
1.00 days to coverFINRA reported short interest of 66,165 shares in CELZ as of the October 30, 2026 settlement, a 19.4% decrease from the prior period — about 1.0 days to cover at its recent average daily volume. On November 20, 2026, 35.4% of CELZ volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Moderate riskFiling-implied dilution signals for CELZ, detected from its recent SEC filings · based on capital-structure filings through 2026-07-24.
Resale Registration of 5.58M Shares · Potential Dilution of ~45.8%
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →